We delineated the importance of AGTR1 signaling in TSC2-deficient cells and demonstrated that AGTR1 blockade could be a potential therapy in LAM and TSC, especially early in the disease when there could be a potential hesitation to commit patients to lifelong therapy with inhibitors of the mTORC1 pathway. The gene discussed is AGTR1; the disease is lymphangioleiomyomatosis.